CompletedNot Applicable

Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

United States1,361 participantsStarted 2012-05

Plain-language summary

Lung cancer is the number one cancer killer in the USA. Early stage lung cancer is asymptomatic. Most patients with lung cancer are usually symptomatic at diagnosis and already have advanced stage disease. Low dose CT screening (LDCT) for high risk individuals has recently been shown to decrease lung cancer mortality by 20%. However, 4 out of 5 lung cancer deaths are not prevented with LDCT screening alone.

Who can participate

Age range50 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Smokers or former smokers * At least 20 pack year history of smoking * Ages 50 - 75 Exclusion Criteria: * Had a CT scan of chest within last 24 months * History of any cancer within 10 yrs (except skin cancer or cervical cancer) * A serious illness that decreases life expectancy to less than 5 years * Any current use of Oxygen * Uncontrolled congestive heart failure or cardiac arrhythmia that would prevent surgery for a lung lesion * Severe COPD or dyspnea that would prevent lung surgery or stereotactic body radiotherapy

What they're measuring

CT alone vs. both Early CDT-Lung test and CT scan.

Timeframe: One year

Trial details

NCT IDNCT01700257

SponsorNational Jewish Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-07

View on ClinicalTrials.gov More High Risk of Developing Lung Cancer trials